Vivodyne opens 'human data center' near San Francisco
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Vivodyne opened what it calls the world's largest "human data center" outside San Francisco last week, using modular robotic labs called HIVE that can grow 20 kinds of human tissue and autonomously dose and monitor them to produce causal biological data missing from today's AI drug training sets.
- Vivodyne has raised just under $80 million across two funding rounds led by Khosla Ventures, spun out of the University of Pennsylvania in 2021, and says it is already achieving twice the throughput of all animal trials being held in the U.S.
- CEO Andrei Georgescu argues the industry needs "a sanity check," noting that 90% of drugs effective enough in animal testing to enter clinical trials don't win FDA approval — making pre-trial human-tissue data worth potentially tens of millions per failed candidate.
- Vivodyne claims its liver cells have 94% predictive accuracy versus human toxicity trials, its airway tissue matches real human tissue 96% of the time, and its bone marrow achieved 100% concordance across tests of 20 different chemotherapy drugs.
- The company is working with multiple unnamed major pharma companies, framing its service like automotive crash tests — giving drugmakers confidence a candidate will pass before committing to expensive clinical trials.
- Even Anthropic CEO Dario Amodei wrote over the weekend that AI cancer-cure claims have become "more cliché than credible," while AlphaFold and its spinoff Isomorphic Labs — now delaying its first trials to end of this year — have yet to produce a new drug despite the Nobel-prize-winning science.
Why it matters: Drugmakers spend tens of millions per clinical trial, and 90% of candidates that pass animal testing still fail FDA approval, per industry figures cited by Vivodyne. If the company's 94-100% tissue-level predictive accuracy holds across its pharma partnerships, early-stage development costs — currently dominated by failed Phase II/III trials — become the direct target for savings.
Ask SkimNews
